In July 2009, Dr. Slepian was appointed chairman of the Science Advisory Board for MicroMed Cardiovascular, manufacturer of the HeartAssist 5™ ventricular assist device.
The CardioWes™Temporary Total Artificial Heart (TAH-t) completely replaces the blood-pumping function of the diseased heart. For patients with end-stage congestive heart failure at imminent risk of death, this device has proven to be a life-saver, allowing them to be "bridged" and supported until a human heart transplant can be performed.
He is recognized for his research and development of novel therapeutics. These include the use of polymeric biomaterials as tissue supports, barriers or means of local drug delivery in tubular organs or organ components, biodegradable stents, drug-eluting stents and the TAH-t.
University of Arizona College of Engineering
Department of Biomedical Engineering 1127 E James E. Rogers Way P.O. Box 210020 Tucson, AZ 85721-0020